Product Name: Pentazocine lactate (CAS NO.17146-95-1)

Molecular Formula: C₁₉H₂₇NO•C₃H₆O₃
Molecular Weight: 375.56g/mol
Mol File: 17146-95-1.mol
EINECS: 241-209-9
Boiling point: 548.8 °C at 760 mmHg
Flash Point: 285.7 °C
Enthalpy of Vaporization: 87.18 kJ/mol
Vapour Pressure: 7.06E-13 mmHg at 25°C
H-Bond Donor: 3
H-Bond Acceptor: 5
Structure Descriptors of Pentazocine lactate (CAS NO.17146-95-1):
  Canonical SMILES: CC1C2CC3=C(C1(CCN2CC=C(C)C)C)C=C(C=C3)O.CC(C(=O)O)O
  Isomeric SMILES: C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O.CC(C(=O)O)O
  InChI: InChI=1S/C19H27NO.C3H6O3/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19;1-2(4)3(5)6/h5-7,12,14,18,21H,8-11H2,1-4H3;2,4H,1H3,(H,5,6)/t14-,18+,19+;/m0./s1 
  InChIKey: QNLDTXPVZPRSAM-DTOXXUQYSA-N

 Pentazocine lactate (CAS NO.17146-95-1) is a CYP450-2D6 inducer that increases the degree of conversion of codeine to morphine (the active metabolite of codeine - a prodrug with no intrinsic activity), in vivo, by approximately a factor of three, increasing the average degree of codeine metabolized to morphine from 10% to 30%  - while synergistically adding to the depressant effects of the codeine.
The mu-opioid-antagonist naloxone was added to preparations containing pentazocine, and the reported incidence of its abuse has declined precipitously since. A more recent recreational route is pentazocine combined with methylphenidate (Ritalin) via the oral route, insufflation or mixed intravenously.

A poison by intraperitoneal route. Human systemic effects. A human skin irritant. When heated to decomposition it emits toxic vapors of NO_x.

 Pentazocine lactate , its CAS NO. is 17146-95-1, the synonyms are  (2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol lactate (salt) ; 2-Hydroxypropanoic acid compd. with (2alpha,6alpha,11R*)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methanol-3-benzocin-8-ol (1:1) ; Liticon ; Pentalgine ; Talwin ; UNII-1P2XIB510O ; 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11R*)-, compd. with 2-hydroxypropanoic acid (1:1) ; Lactic acid, compd. with 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol (1:1) ; Lactic acid, compound with (2alpha,6alpha,11R*)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzocin-8-ol (1:1) ; Propanoic acid, 2-hydroxy-, compd. with (2alpha,6alpha,11R*)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methanol-3-benzocin-8-ol (1:1) .